merck stapled peptide p53 patent proteins - sj-peptides Stapled peptides Merck Stapled Peptide p53 Patent: Revolutionizing Cancer Therapy

melitane-and-darkenyl-peptide The field of oncology is witnessing a significant paradigm shift with the advent of innovative therapeutic strategies, and Merck stapled peptide p53 patent research stands at the forefront of this revolution2025年8月8日—The novel stapled peptide PM2prevents MDM2 from suppressing wild-type p53, and is thus a promising agent for therapeutic combination with EBRT.. At its core, this research focuses on the development of stapled peptides designed to harness the power of the p53 tumor suppressor protein, a critical regulator of cell growth and a key player in cancer development作者：TY Yuen·2019·被引用次数：35—We recently published a series ofstapled peptidesguided by computer simulations that specifically targeted thep53-Mdm2 binding groove. These .... The groundbreaking work, often associated with Merck, and other research institutions, centers on stabilizing the alpha-helical conformation of peptides, thereby enhancing their therapeutic potentialDiscovery of MK-4688: an Efficient Inhibitor of the HDM2–p53 ....

One of the primary mechanisms by which these stapled peptides exert their effect is by interfering with the interaction between p53 and its negative regulators, primarily MDM2 and MDMX (also known as MDM4). In healthy cells, p53 acts as a guardian of the genome, initiating cell cycle arrest or apoptosis in response to DNA damage2023年2月26日—Accordingly, we sought to uncoverstapled peptide'design rules' by studying an existing class of cell-active peptides that disrupt thep53/Mdm2 .... However, in many cancers, p53 function is compromised, often due to overexpression of MDM2, which targets p53 for degradation. Stapled peptides are engineered to mimic the natural interaction domain of p53, effectively blocking the binding of MDM2 to p53. This disruption prevents the ubiquitizing and subsequent destruction of p53, leading to its stabilization and reactivation.

The scientific literature highlights numerous advancements in this area. Patents such as US9527896B2 and US9517252B2 describe stabilized p53 peptides and uses thereof, as well as p53 activating peptides, underscoring the foundational research in this domain. These p53 activating peptides are crucial for restoring the tumor-suppressive function of p53. Furthermore, research into non-membrane disruptive and p53 activating stapled peptides (as seen in patent applications like WO2016130092A1) addresses the challenge of delivering these therapeutic agents effectively into cells without causing cellular damage.

A prominent example in clinical development is ALRN-6924.2013年9月26日—Bernal et al.,Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide. JAm ChemSoc. Mar. 7, 2007: 129(9):2456-7. Epub Feb ... This cell-penetrating stapled alpha-helical peptide is designed to equipotently disrupt the interaction between the p53 tumor suppressor protein and its regulatorsStapled peptides as scaffolds for developing radiotracers .... Preliminary results from studies involving ALRN-6924, the first-in-class clinical stage stapled peptide, have shown promise.These cross-linked peptidomimetic macrocycles contain at least two modified amino acids that together form an intramolecular cross-link that stabilizes the ... Its structural stabilization in an alpha-helical configuration is key to its ability to mimic the inhibitor of the crucial HDM2–p53 interaction. Research by authors like YS Chang has demonstrated the development of potent dual inhibitors of MDM2 and MDMX, such as ATSP-7041, which effectively activate the p53 pathway in tumors both in vitro and in vivo. This stapled alpha-helical peptide lead molecule represents a significant step forward in cancer therapeutics for cancers possessing intact p53 function.Rationale: Althoughstapled peptidesoffer a powerful solution to overcome the susceptibility of linear peptides to proteolytic degradation and improve their ...

The development of these stapled peptides is not without its complexities. Researchers are continuously exploring design-rules for stapled peptides with in vivo activity and their applications. This includes understanding stereoisomerism in stapled peptide inhibitors of the p53–Mdm2 binding groove, as well as investigating the use of both L- and D-amino acids in molecules that bind to Mdm2 and MdmX to displace p53. The ability of these stapled peptides to overcome the susceptibility of linear peptides to proteolytic degradation and improve their pharmacokinetic profiles is a major advantage(PDF) The Stapled Peptide PM2 Stabilizes p53 Levels and ....

Beyond direct inhibition of the p53/MDM2 interaction, the versatility of stapled peptides is being explored in various applications. For instance, stapled peptide-based radiotheranostic agents are being developed for PET-imaging guided radiotherapy of p53 mutant cancers, as highlighted in research by K Hu. Moreover, a stapled peptide like PM2 has shown potential in preventing MDM2 from suppressing wild-type p53, making it a promising agent for therapeutic combinations.Stapled peptides with improved potency and specificity that ...

The overarching goal of Merck stapled peptide p53 patent research and its broader scientific exploration is to leverage the inherent tumor-suppressive power of p53. By stabilizing p53 levels and reactivating the p53 tumor suppressor pathway by a stapled p53 peptide, these innovative therapeutics offer a new avenue for treating a wide range of cancers. The continuous refinement of peptide design, delivery mechanisms, and a deeper understanding of protein-protein interactions at the molecular level, particularly involving proteins like p53 and MDM2, are paving the way for more effective and targeted cancer therapies.